MediCane Health Inc. Announce First Patient Enrolled in a Phase IIa Clinical Trial of MediCane’s Balanced T3:C3 Oral Medical Cannabis Oil for Symptom Relief of Behavioral and Psychological Symptoms of Dementia (BPSD)

KFAR SAVA, Israel–(BUSINESS WIRE)–MediCane Health Inc. (along with its subsidiaries together referred to as “MediCane”) today announced the recruitment of the first patient for its clinical study d…